Famitinib malate is a highly effective multi-targeted tyrosine kinase inhibitor with superior pharmacological and toxicological properties. Phase I clinical trials have shown that famitinib has shown a relatively good safety and tolerability profile in patients with advanced solid tumors, with tolerable adverse effects. The drug’s target of action is similar to sunitinib (sotan), a currently approved and marketed drug for the treatment of G1/G2 stage gastroenteropancreatic neuroendocrine tumors. The study had no control group and all patients were treated with famitinib. Patients with gastroenteropancreatic neuroendocrine tumors who meet the following criteria can be enrolled in the clinical study: 1. advanced or metastatic gastroenteropancreatic neuroendocrine tumors of G1 or G2 grade with inoperable pathology; 2. 18-75 years of age with measurable lesions; 3. first- or second-line therapy; 4. no other molecular targeted therapy; 5. normal function of major organs.